$3B F-SHRP program launches in New York

8 October 2006

A five-year $3.0 billion proposal by New York State to reorient its Medicaid program has been approved by Mike Leavitt, the federal Secretary of Health and Human Services. The changes would mean that more people would be provided with care in their own homes, which reduces waste, improves patient satisfaction and improves the Medicaid program's economic viability. The Federal-State Health Reform Partnership was developed by state and federal officials.

Mark McClellan, the Centers for Medicare and Medicaid Services Administrator, said: "this reform program embodies key principles to keep Medicaid up to date and sustainable into the future." He added: "health care is increasingly about coordination of services and preventing complications before they happen, not just paying more for services in costly settings, and we are pleased to support the State of New York."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight